Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
Holding SPRB?
Track your performance easily
SPRB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.41 - $5.95
Previous Close$0.46
Volume334.81K
Average Volume (3M)427.02K
Market Cap
$18.84M
Enterprise Value-$48.30M
Total Cash (Recent Filing)$69.68M
Total Debt (Recent Filing)$2.54M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Nov 20, 2024EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding41,302,599
10 Day Avg. Volume235,764
30 Day Avg. Volume427,022
Standard Deviation0.40
R-Squared0.09
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.32
Price to Sales (P/S)1.97
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-5.10
Enterprise Value/Gross Profit-4.78
Enterprise Value/Ebitda1.12
Forecast
1Y Price Target
$2.33Price Target Upside416.06% Upside
Rating ConsensusHold
Number of Analyst Covering4
Spruce Biosciences News
PremiumCompany Announcements
Spruce Biosciences Faces Nasdaq Delisting Threat Over Low Stock Prices
Bulls Say, Bears Say
Bulls Say
Clinical TrialsManagement has reported higher compliance than in the previous trial and patients have good disease control, indicating a chance for positive outcomes in the '204 trial.
Drug DevelopmentTildacerfont could be the second CAH drug to market.
Financial PerformanceSpruce Biosciences ended 2Q24 with $69.7M in cash and cash equivalents, which is expected to be sufficient to fund operations at least through the end of 2025 based on the company's current strategic plan.
Bears Say
Clinical Trial ResultsSPRB reported disappointing Phase 2b CAHmelia-203 data in March 2024.
Drug Compliance50% of patients had less than 80% compliance.
Regulatory And Commercial RisksRisks include failure to show clinical impact in the Phase 2b trials of tildacerfont, inability to obtain timely regulatory approval, setbacks in other clinical development programs, slower-than-anticipated commercial uptake, and medium- to long-term dilution risk.
---
Ownership Overview
44.72% Insiders
2.82% Mutual Funds
33.75% Other Institutional Investors
18.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $0.41 and its highest was $5.95 in the past 12 months.
What is Spruce Biosciences’s market cap?
Currently, no data Available
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Nov 20, 2024 which is in 61 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Aug 12, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.1.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -$0.25.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 41,302,600 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went up 2.381%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at N/A.
---
Spruce Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.33 (416.06% Upside)
$2.33 (416.06% Upside)
Blogger Sentiment
Bullish
SPRB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.46%
12-Months-Change
Fundamentals
Return on Equity
-55.36%
Trailing 12-Months
Asset Growth
-40.05%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
---
SPRB Earnings Call
Q4 2024
0:00 / 0:00
---
SPRB Stock 12 Month Forecast
Average Price Target
$2.33
▲(416.06% Upside)
Technical Analysis
Viridian Therapeutics
―
Crinetics Pharmaceuticals
―
Annexon Biosciences
―
Bioxcel Therapeutics
―
Best Analysts Covering SPRB
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-35.45%
reiterated a buy rating 9 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -35.45% per trade.
---